Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury: Laboratory investigation

Journal of Neurosurgery: Spine

Volumn 7, Issue 6, 2007, Pages 645-651

  Grasso, Giovanni ^a,c   Meli, Francesco ^a   Fodale, Vincenzo ^b   Calapai, Gioacchino ^b   Buemi, Michele ^b   Iacopino, Domenico G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Darbepoetin alfa; Erythropoietin; Neuroprotection; Peripheral nerve injury; Sciatic nerve

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; MALE; MUSCLE ACTION POTENTIAL; MUSCLE ATROPHY; NERVE ENDING; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE INJURY; RAT; SCIATIC NERVE INJURY;

ACTION POTENTIALS; ANIMALS; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MALE; MUSCLE, SKELETAL; NERVE CRUSH; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SCIATIC NERVE; TIME FACTORS;

EID: 37349057458     PISSN: 15475654     EISSN: None     Source Type: Journal    
DOI: 10.3171/SPI-07/12/645     Document Type: Article

References (51)

1. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952:128-134, 2002
2. Allaf ME, Hoke A, Burnett AL: Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 174:2060-2064, 2005
3. Ambron RT, Walters ET: Priming events and retrograde injury signals. A new perspective on the cellular and molecular biology of nerve regeneration. Mol Neurobiol 13:61-79, 1996
4. Belayev L, Khoutorova L, Zhao W, Vigdorchik A, Belayev A, Busto R, et al: Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 36:1071-1076, 2005
5. Bervar M: Video analysis of standing - an alternative footprint analysis to assess functional loss following injury to the rat sciatic nerve. J Neurosci Methods 102:109-116, 2000
6. Boran BO, Colak A, Kutlay M: Erythropoietin enhances neurological recovery after experimental spinal cord injury. Restor Neurol Neurosci 23:341-345, 2005
7. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000
8. Buemi M, Aloisi C, Cavallaro E, Corica F, Floccari F, Grasso G, et al: Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. J Nephrol 15:97-103, 2002
9. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, et al: Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 103:275-282, 2002
10. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-4806, 2003
11. Campana WM, Li X, Shubayev VI, Angert M, Cai K, Myers RR: Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 23:617-626, 2006
12. Campana WM, Myers RR: Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 18:1497-1506, 2003
13. Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, et al: Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur J Pharmacol 437:147-150, 2002
14. Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263, 2002
15. D'Andrea RJ, Gonda TJ: A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit. Exp Hematol 28:231-243, 2000
16. Digicaylioglu M, Lipton SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647, 2001
17. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Suppl 3):3-13, 2001
18. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA: Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299, 2003
19. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505, 2002
20. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, et al: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100:6741-6746, 2003
21. Fu SY, Gordon T: The cellular and molecular basis of peripheral nerve regeneration. Mol Neurobiol 14:67-116, 1997
22. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al: Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 99:9450-9455, 2002
23. Grasso G: Neuroprotective effect of recombinant human erythropoietin in experimental subarachnoid hemorrhage. J Neurosurg Sci 45:7-14, 2001
24. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, et al: Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99:5627-5631, 2002
25. Grasso G, Passalacqua M, Sfacteria A, Conti A, Morabito A, Mazzullo G, et al: Does administration of recombinant human erythropoietin attenuate the increase of S-100 protein observed in cerebrospinal fluid after experimental subarachnoid hemorrhage? J Neurosurg 96:565-570, 2002
26. Grasso G, Sfacteria A, Brines M, Tomasello F: A new computed-assisted technique for experimental sciatic nerve function analysis. Med Sci Monit 10:BR1-BR3, 2004
27. Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N, et al: Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 4:310-318, 2006
28. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, et al: Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 99:10659-10664, 2002
29. Juul SE, Anderson DK, Li Y, Christensen RD: Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43:40-49, 1998
30. Juul SE, Yachnis AT, Christensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249, 1998
31. Kanaan NM, Collier TJ, Marchionini DM, McGuire SO, Fleming MF, Sortwell CE: Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease. Brain Res 1068:221-229, 2006
32. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M: Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276:39469-39475, 2001
33. Keswani SC, Buldanlioglu U, Fischer A, Reed N, Polley M, Liang H, et al: A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 56:815-826, 2004
34. Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, et al: Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 83:224-228, 2003
35. Ledbetter DJ, Juul SE: Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 35:178-182, 2000
36. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242, 2004
37. Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD: Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 40:376-380, 1996
38. Marti HH: Erythropoietin and the hypoxic brain. J Exp Biol 207:3233-3242, 2004
39. Mikati MA, El Hokayem JA, El Sabban ME: Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. Epilepsia 48:175-181, 2007
40. Patton J, Reeves T, Wallace J: Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9:451-458, 2004
41. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R: A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 25:2781-2796, 2003
42. Sekiguchi Y, Kikuchi S, Myers RR, Campana WM: ISSLS prize winner: Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 28:2577-2584, 2003
43. Shamash S, Reichert F, Rotshenker S: The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci 22:3052-3060, 2002
44. Shingo T, Sorokan ST, Shimazaki T, Weiss S: Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21:9733-9743, 2001
45. Sirén AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044-4049, 2001
46. Springborg JB, Ma X, Rochat P, Knudsen GM, Amtorp O, Paulson OB, et al: A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 135:823-829, 2002
47. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, et al: Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24:453-460, 2004
48. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971-975, 2003
49. Wagner R, Myers RR: Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7:2897-2901, 1996
50. Wagner R, Myers RR: Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 73:625-629, 1996
51. Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 24:450-455, 2001